DNA & Genetics uniQure Staggers at FDA, Recursion’s Microglia Map, Leadership TransitionsBy adminNovember 8, 20250 uniQure’s “game changing” data announced in September, which showed significant slowing of Huntington’s disease (HD) progression in patients treated with…
DNA & Genetics uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy CandidateBy adminNovember 3, 20250 uniQure has acknowledged that what it called “game changing” data in September showing significant slowing of Huntington’s disease (HD) progression…
DNA & Genetics uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s DataBy adminSeptember 28, 20250 The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in…
